id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10172 R37177 |
Blotière (Phenobarbital) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Talipes equinovarus | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
7.53 [0.36;158.21] C excluded (control group) |
0/80 2/2,997 | 2 | 80 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10042 R36313 |
Blotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019 | Talipes equinovarus | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 7.03 [0.44;113.37] C | 0/80 1,677/1,875,733 | 1,677 | 80 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9172 R31573 |
Van der Pol (Phenobarbital) (Controls unexposed, disease free), 1991 | Talipes | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
4.74 [0.09;251.42] C excluded (control group) |
0/12 0/55 | 0 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9173 R31598 |
Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 | Talipes | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.87 [0.03;100.54] C | 0/12 0/22 | 0 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 4.55 [0.47;44.55] | 1,677 | 92 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital) (Controls unexposed NOS) (Mixed indications; 2: Phenobarbital) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9172, 10172